Anavex (AVXL) gets CHMP negative trend vote on blarcamesine

Anavex Life Sciences reported a regulatory setback: the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote following the oral explanation for the Marketing Authorization Application (MAA) of blarcamesine.

Rhea-AI Filing Summary

Anavex Life Sciences reported a regulatory setback: the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote following the oral explanation for the Marketing Authorization Application (MAA) of blarcamesine.

The company plans to request a re-examination once the CHMP opinion is formally adopted and to provide additional biomarker data in line with feedback from CHMP, EMA, and the Alzheimer’s disease community. A press release with further details was provided as Exhibit 99.1.

Insights

Biopharma regulatory analyst

Preliminary negative CHMP signal; re-examination planned with biomarker data.

The CHMP issued a negative trend vote after the oral explanation for the blarcamesine MAA. A trend vote is not the final opinion, but it indicates the current direction of committee discussions and suggests hurdles remain for approval.

Anavex plans to request re-examination after formal adoption of the opinion, including submitting relevant biomarker data per November 14, 2025 disclosures. Outcomes can change during re-examination if new analyses address concerns.

Investors should note the path forward depends on the CHMP’s final opinion and the strength of any additional biomarker evidence submitted during re-examination.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Anavex (AVXL) announce regarding the EMA review?

The CHMP issued a negative trend vote following the oral explanation for the blarcamesine MAA.

Is the CHMP negative trend vote a final decision for AVXL?

No. It is not the final opinion. Anavex plans to request a re-examination after formal adoption of the opinion.

What product is affected in the AVXL update?

The update concerns the MAA for blarcamesine.

What is Anavex’s next step after the CHMP signal?

Anavex intends to seek re-examination and provide relevant biomarker data based on CHMP/EMA feedback.

Where can I read more details on the AVXL announcement?

A press release dated November 14, 2025 was furnished as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 07:42 AM Learn about SEC filing dates

false 0001314052 0001314052 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)

Nevada	001-37606	98-0608404
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

630 5th Avenue

20th Floor

New York, NY 10111

(Address of principal executive offices) (Zip Code)

1-844-689-3939 

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		AVXL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 14, 2025, Anavex Life Sciences Corp. (the “Company”) issued a press release announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a negative trend vote following an oral explanation of the Company’s Marketing Authorization Application (MAA) for blarcamesine.

The Company intends to request a re-examination of the CHMP opinion upon its formal adoption, including providing relevant biomarker data, based on feedback and continued guidance from the CHMP, EMA and the Alzheimer’s disease community.

A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference, including the cautionary statement on forward-looking statements included in the press release.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT NO.		DESCRIPTION		LOCATION
99.1		Press release dated November 14, 2025		Filed herewith
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.
By:	/s/ Christopher Missling
	Name: Christopher Missling, PhD
	Title: Chief Executive Officer

Date: November 14, 2025